Thesan Pharmaceuticals, a biotech firm that develops therapies for skin conditions, raised $49 million for its Series B round led by existing investor Novo Ventures and joined in by SV Life Sciences, Lundbeckfond Ventures and Novartis Venture Fund.
SV Life Sciences
Breaking News
Subscribe to VCpost newsletter
Most Popular
- Vladimir Putin: Russia Becoming 'New Global Growth Center' Despite Western Isolation
- Investing Experts Say Now Is the Best Time to Invest in Small- and Midsize-Company Stocks — Here's Why
- Why Billionaire Tech Leader Romesh Wadhwani Is Investing $1 Billion on AI's Future
- Swiss Bank Banque Pictet Admits to Conspiring With US Taxpayers to Hide Over $5.6 Billion From IRS
- Maximizing Social Security Retirement Benefits: Experts Reveal Strategies to Get Bigger Monthly Checks
- Elon Musk's AI Startup X.AI Seeks to Raise $1 Billion From Equity Investors
- US Economy Is Still Robust With Labor Market Adding 199,000 Jobs in November
- Amazon Removes Venmo as Payment Method, Causing PayPal Shares to Drop
